期刊
TRENDS IN ENDOCRINOLOGY AND METABOLISM
卷 30, 期 10, 页码 756-766出版社
ELSEVIER SCIENCE LONDON
DOI: 10.1016/j.tem.2019.07.014
关键词
-
资金
- Ministerio de Ciencia, Innovacion y Universidades - Fondo Europeo de Desarrollo Regional (FEDER) [SAF2016-80286-R]
Musculoskeletal disorders represent an elevated socioeconomic burden for developed aging societies. Osteoporosis (OP) has been treated with antiresorptive therapies or with teriparatide that was until recently the only anabolic therapy. However, approval of osteoporosis treatment in postmenopausal women with abaloparatide, which is an analog of parathyroid hormone related peptide (PTHrP), has created a new alternative for OP management. The success of this new treatment is related to differential mechanisms of activation of PTH receptor type 1 (PTH1R) by abaloparatide and PTH. Here, we address the distinguishing mechanisms of PTH11 activation; the effects of PTH1R stimulation in osteoblast, osteocytes, and chondrocytes; the dif ferences between PTH and abaloparatide actions on PTH1R; potential safety concerns; and future perspectives about abaloparatide use in other musculoskeletal disorders.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据